RPG Life Sciences launches IMPULSE, strengthens cardio-vascular portfolio

In its efforts to spruce up its marketing set-up, RPG Life Sciences, a RPG Group Company, launched its third vertical, Impulse, to focus on the growing Cardio-metabolic segment of the pharmaceuticals business. This was preceded by the launch of Empathy (neuropsychiatry division) and Neolife (Oncology division) last month.

RPGLS is ranked 39th amongst the pharma companies focusing on the Cardiovascular segment in India, with well known brands like Aldactone and Spiromide. The Cardio-metabolic division, Impulse, will help improve its presence in this segment substantially with a team of 115 people across India.

The objective of the division is to help RPGLS to be amongst the top 20 companies in cardiovascular therapy segment in India by 2015.

This will be achieved by launching new products to cater to various therapeutic needs in Cardio-metabolic segment and aggressive marketing strategies.

The launch of Impulse will further fortify the company’s aggressive growth plans.

About RPG Life Sciences Ltd
RPG Life Sciences is an important player in formulations, bulk drugs and Biotech business. The company is present both in the domestic as well as in the international markets. Product exports range from Europe, Latin America, Africa, Canada to the South East Asian countries.

About RPG Enterprises
RPG Enterprises is one of India’s leading business groups with a turnover of Rs 16,000 crore. The Group has presence in sectors like Power, Tyres, Retail, IT, Infrastructure, Carbon Black, Speciality & Entertainment.